Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of ...

Unexplained tingling, known to doctors as paresthesia, is often only temporary and harmless. But it can be a symptom of ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis ...

Adicet Bio (NASDAQ:ACET), a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7 ...

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q2 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its ...

Autolus Therapeutics ( ($AUTL) ) has released its Q2 earnings. Here is a breakdown of the information Autolus Therapeutics presented to its ...

Using data from over 1.5 million patients from 47 studies, the researchers analysed the association between four autoimmune ...

Net loss was $23.0 million, or $0.31 per basic and diluted share, for the second quarter of 2025. This net loss includes non-cash charges of $3.4 million that consisted primarily of share-based ...